AMENDMENTS TO THE CLAIMS

Please add claims 17-27 as shown in the following listing of claims, which will replace all prior versions and listings of claims in the application.

Listing of claims:

1 (previously presented). A method of treating basal cell carcinoma in a subject, the method comprising administering to the subject an amount of an IRM compound effective for treating basal cell carcinoma wherein the IRM compound is administered in a treatment cycle that comprises at least five consecutive days in which the IRM compound is administered and at least two days in which the IRM compound is not administered.

2. – 6. (canceled)

7 (original). The method of claim 1 wherein the method comprises at least two treatment cycles.

8 (original). The method of claim 7 wherein the method comprises at least six treatment cycles.

9 (original). The method of claim 1 wherein administering the IRM compound comprises applying one dose of the IRM compound per day.

10 (original). The method of claim 1 wherein administering the IRM compound comprises topically applying the IRM compound to a treatment area that includes a lesion.

11 (original). The method of claim 10 wherein the IRM compound is applied in a formulation that comprises from about 1% to about 10% IRM compound.

12 (original). The method of claim 11 wherein the formulation comprises about 5% IRM compound.

13 (original). The method of claim 11 wherein the formulation is applied to the treatment area for from about two hours to about 24 hours.

14 (original). The method of claim 13 wherein the formulation is applied to the treatment area for from about six hours to about twelve hours.

15 (original). The method of claim 11 wherein the formulation is applied to the treatment area for about eight hours.

16 (original). The method of claim 10 wherein the treatment area further comprises skin at least 0.5 cm beyond the margin of the lesion.

17 (new). The method of claim 1, wherein the IRM compound comprises an imidazoquinoline.

18 (new). The method of claim 1, wherein the IRM compound comprises an imidazoquinoline amine or an imidazoquinoline amide.

19 (new). The method of claim 18, wherein the IRM compound comprises 1-(2-methylpropyl)-1*H*-imidazo[4,5-*c*]quinolin-4-amine.

20 (new). The method of claim 1, wherein the basal cell carcinoma comprises superficial basal cell carcinoma.

21 (new). A method of treating basal cell carcinoma in a subject, the method comprising administering to the subject an amount of an IRM compound effective for treating basal cell carcinoma wherein the IRM compound is administered in a treatment cycle that comprises at least five consecutive days in which the IRM compound is administered and at least two days in which the IRM compound is not administered, wherein:

(a) the method comprises at least six treatment cycles;

(b) administering the IRM compound comprises topically applying one dose of the IRM compound per day to a treatment area that includes a lesion;

(c) the IRM compound is applied in a formulation that comprises from about 1% to about 10% IRM compound;

(d) the formulation is applied to the treatment area for from about six hours to about twelve hours;

(e) the IRM compound comprises an the IRM compound comprises an imidazoquinoline amine or an imidazoquinoline amide.

22 (new). The method of claim 21, wherein the formulation comprises about 5% IRM compound.

23 (new). The method of claim 21, wherein the formulation is applied to the treatment area for about eight hours.

24 (new). The method of claim 21, wherein the treatment area further comprises skin at least 0.5 cm beyond the margin of the lesion.

25 (new). The method of claim 21, wherein the IRM compound comprises 1-(2-methylpropyl)-1*H*-imidazo[4,5-*c*]quinolin-4-amine.

26 (new). The method of claim 1, wherein the basal cell carcinoma comprises superficial basal cell carcinoma.

27 (new). A method of treating superficial basal cell carcinoma in a subject, the method comprising administering to the subject an amount of an IRM compound effective for treating superficial basal cell carcinoma wherein the IRM compound is administered in a treatment cycle that comprises at least five consecutive days in which the IRM compound is administered and at least two days in which the IRM compound is not administered, wherein:

(a) the method comprises at least six treatment cycles;

(b) administering the IRM compound comprises topically applying one dose of the IRM compound per day to a treatment area that includes a lesion;

(c) the IRM compound is applied in a formulation that comprises about 5% IRM compound;

(d) the formulation is applied to the treatment area for from about six hours to about twelve hours;

(e) the IRM compound comprises an the IRM compound comprises imiquimod.

28 (new). The method of claim 27, wherein the formulation is applied to the treatment area for about eight hours.

29 (new). The method of claim 27, wherein the treatment area further comprises skin at least 0.5 cm beyond the margin of the lesion.